Brimonidine in the treatment of glaucoma and ocular hypertension
Open Access
- 1 December 2006
- journal article
- Published by Taylor & Francis Ltd in Therapeutics and Clinical Risk Management
- Vol. 2 (4), 337-346
- https://doi.org/10.2147/tcrm.2006.2.4.337
Abstract
Dove Press is a member of the Open Access Initiative, specializing in peer reviewed Medical Journals. View articlesor submit your research for publishingKeywords
This publication has 67 references indexed in Scilit:
- Brimonidine and Timolol Fixed-Combination Therapy Versus Monotherapy: A 3-Month Randomized Trial in Patients with Glaucoma or Ocular HypertensionJournal of Ocular Pharmacology and Therapeutics, 2005
- 24-Hour Intraocular Pressures with Brimonidine Purite versus Dorzolamide Added to Latanoprost in Primary Open-Angle Glaucoma SubjectsOphthalmology, 2005
- Optic nerve and neuroprotection strategiesEye, 2004
- Brimonidine purite 0.15% versus dorzolamide 2% each given twice daily to reduce intraocular pressure in subjects with open angle glaucoma or ocular hypertensionBritish Journal of Ophthalmology, 2004
- Eficacia de brimonidina 0,2% y dorzolamida 2% como tratamiento adyuvante a un beta-bloqueanteArchivos de la Sociedad Española de Oftalmología, 2004
- Effects of common ophthalmic preservatives on ocular healthAdvances in Therapy, 2001
- A comparison of dorzolamide–timolol combination versus the concomitant drugsAmerican Journal of Ophthalmology, 2000
- The evolving pharmacotherapeutic profile of brimonidine, an 2-adrenergic agonist, after four years of continuous useExpert Opinion on Pharmacotherapy, 2000
- The Effectiveness and Safety of Brimonidine as Mono-, Combination, or Replacement Therapy for Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Post Hoc Analysis of an Open-Label Community TrialJournal of Ocular Pharmacology and Therapeutics, 2000
- Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: Year-three resultsClinical Therapeutics, 2000